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Cultures were used for evaluation of antiatherogenic drugs. Numerous
substanceswerereportedtolowerserumatherogenicity:statins,trapidil,
calcium antagonists, garlic derivatives etc. On the contrary, beta-
blockers, phenothiazines and oral hypoglycemics were reported to be
pro-atherogenic. Known antiatherogenic agents can influence lipid
metabolismandcholesterolsynthesis,intestinalabsorptionorendothe-




hypercholesterolemia, inefficient clearance of LDL-cholesterol by cells
predisposes to atherosclerosis. Accordingly, if a pharmacological agent
reduces cholesterol uptake by cells in vitro, it should be expected to
elevate cholesterol in vivo. Validity of clinical recommendations, based
on serum atherogenicity testing in cell monocultures, is therefore
questionable.Theseconsiderationspertainalsotothedrugsdeveloped
on the basis of the cell culture experiments.
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Zusammenfassung
In einer großen Studienserie wurde berichtet, dass Kultivierung der
Glattmuskelzellen mit dem Serum von Atherosklerosekranken eine in-
trazelluläreLipidansammlungverursachte,währendSerumvongesun-
den Kontrollsubjekten keine derartige Wirkung hatte. Die Zellkulturen
wurden für die Bewertung anti- und pro-atherogener Wirkung von Arz-
neimitteln und anderer Substanzen verwendet. Mehrere Wirkstoffe
verminderten angeblich die Serumatherogenität in den Zellkulturen:
Statine,Trapidil,Calciumantagonisten,Knoblauchderivateundandere.
Betablocker,PhenothiazineundoraleHypoglykämikawirktenhingegen
pro-atherogen. Es ist jedoch bekannt, dass anti-atherosklerotische
Arzneimittel auf folgende Punkte einwirken konnen: Lipidstoffwechsel
und Cholesterinsynthese, intestinale Resorption von Lipiden und die
endothothelassoziierten Mechanismen. Alle diese Angriffsziele sind in
den Zellmonokulturen nicht vorhanden. Entzündungserscheinungen,
die von einigen anti-atherosklerotischen Wirkstoffen moduliert werden
können, werden auch nicht reproduziert. In vivo ist das Verhältnis zwi-
schen der Cholesterinaufnahme von Zellen und der Atherogenese um-
gekehrt: z.B. veranlagt bei der familiären Hypercholesterinnämie eine
vom LDL-Rezeptordefekt bedingte unzureichende Clearance von LDL-
Cholesterin zur Atherosklerose. Wenn ein pharmakologischer Wirkstoff
die Cholesterinaufnahme von Zellen senkt, sollte er in vivo den Choles-
terinspiegel im Blut erheben. Die Zuverlässigkeit der aufgrund obenge-
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Letter to the Editor OPEN ACCESSnannter Zellkulturstudien formulierten klinischen Empfehlungen er-
scheintalsofraglich.DasbetrifftauchdieArzneimittel,dieaufderBasis
der Zellkulturexperimente entwickelt wurden.
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Letter to the Editor
Strategies to treat atherosclerosis pharmacologically
should take its multifactorial etiology into account [1].
Atherogenesis involves many cell types interacting with
each other and with extracellular matrix [2]. Therefore,
results obtained in studies on a single cell type should
be considered with caution when extrapolated to the
whole body. A large series of studies, having become in-
ternationally known in 1986 after the publication in The
Lancet [3], has been continued until today [4]. Cultures
of smooth muscle cells from human aorta and, in some
studies, of peritoneal macrophages, were used as an in
vitro model for testing of serum atherogenicity and anti-
or pro-atherogenic action of various substances. The fol-
lowing,amongotherthings,wasreported:within24hours
of cultivation with diluted (40%) sera of coronary athero-
sclerosis patients, the total intracellular cholesterol (Ch)
increased twofold to fivefold [5]. Low density lipoproteins
(LDL)frompatientswithcoronaryatherosclerosiscaused
a twofold to fourfold rise in cholesteryl esters in cultured
humanbloodmonocytesandintimalsmoothmusclecells
isolated from the normal aorta [6], [7]. Cultivation with
the sera or LDL from healthy individuals failed to induce
intracellular lipid accumulation [5], [6]. Furthermore,
calcium antagonists (verapamil, nifedipine, darodipine,
isradipine,diltiazem,etc.)reducedtheChlevelincultured
cells and, at the same time, lowered the incorporation of
3H-thymidine by the cells, which was interpreted as de-
creased cell proliferation [8]. It was concluded that calci-
um antagonists manifested a direct antiatherosclerotic
effectinculture[8].Furthermore,beta-blockers(propran-
olol,alprenolol,metoprolol,atenolol,pindolol,andtimolol)
caused a 1.5- to 2-fold rise in Ch level of cultured cells
and stimulated their proliferation [8]. Apart from direct
admixture of a tested substance to the culture medium,
an “ex vivo” model was used: within 2–4 h after an oral
administration of a beta-blocker (propranolol), plasma
became atherogenic i.e. its addition to the cell culture
medium induced intracellular Ch accumulation and
stimulatedproliferationoftheculturedcells.Atthesame
time, blood plasma of patients receiving calcium antag-
onistsacquiredantiatheroscleroticpropertiesmanifested
by its ability to lower the intracellular Ch and to inhibit
cellsproliferationinaculture[8].Anotherexample:garlic
extractaddedtothemedium,wheresmoothmusclecells
from atherosclerotic plaques had been cultured, signifi-
cantlyreducedtheChlevelinthecellsandinhibitedtheir
proliferation. Blood serum taken from patients 2 hours
after an oral administration of 300 mg of garlic powder
significantlyloweredChaccumulationintheculturedcells
[9].Remarkably,infiltrationofculturedcellsbylipidswas
reported to be associated with their increased prolifera-
tion: in the cultures of smooth muscle cells taken from
zones of fatty infiltration and fatty streaks in the human
aortic intima, the thymidine index exceeded the normal
value 4.5- and 3-fold respectively [10]. Pharmacological
agents, modifying intracellular lipid accumulation, influ-
enced cell proliferation in the same direction [11]. In
general pathology, however, fatty infiltration is seen as a
manifestation of cell damage (degeneration) [12], which
can hardly be expected to come along with enhanced
proliferation.
Furthermore, recommendations for practice were formu-
latedonthebasisofcellcultureexperiments[13],includ-
ing drug dosage: “To decrease atherogenic potential of
serum and to maintain it at a low level, verapamil should
be administered at a dose of 40 mg 5 times daily with a
4- to 5-hour interval between doses.” [13] This recom-
mendation should be seen within the scope of a broader
question,whetherdatafromcellularmodelsmaybeused
directlyforclinicalrecommendationswithoutclinicaltrials.
Cellular systems in pharmacological research are essen-
tial for initial evaluation of drugs. However, their use to
predict a response of the whole body is limited. A re-
sponse of cellular systems to an agent influencing trans-
port across the plasma membrane can have opposite
effects in cells compared to the whole body [14]. As an
explanation for atherogenicity of serum from patients
with coronary atherosclerosis, a causative role of Ch-
containing immune complexes was maintained [15].
However, among the mechanisms of atherogenesis in-
ducedbyimmunecomplexes,discussedintheliterature,
are inflammatory phenomena such as release of proin-
flammatory cytokines from macrophages, increase in
adhesion molecules and dysfunction of endothelial cells
[1], [16], [17], [18], which are not reproduced in the cell
monocultures. Known action mechanisms of antiathero-
genic or lipid-lowering drugs include regulation of Ch
synthesis, lipid metabolism in the liver, intestinal absorp-
tion of lipids or endothelial functions [1], [19], [20]. All
these targets are absent in the cell cultures. In addition,
drugs like statins have numerous “pleiotrophic effects”
that can be beneficial [1] but are not reproducible in the
cultures. Inflammatory phenomena, addressed by some
antiatherogenicagents[2],[21],arealsonotreproduced
bythismodel.Invivo,therelationshipbetweenChuptake
by cells and atherogenesis is inverse rather than direct.
For example, in familial hypercholesterolemia, caused by
abnormalityoflipoproteinreceptors,ineffectiveclearance
of LDL-Ch from serum causes hypercholesterolemia and
predisposes to atherosclerosis [22]. Moreover, up-regu-
lation of LDL receptors (and, correspondingly, of the LDL-
Ch uptake by cells) is one of the therapeutic strategies
foratherosclerosis[23].Accordingly,ifapharmacological
agent reduces Ch uptake by cells in vitro, it should be
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words, pharmacologic agents displaying an “antiathero-
genic” effect in cell cultures should be expected to have
a pro-atherogenic effect in vivo. Therefore, conclusions
and recommendations, formulated on the basis of the
cell culture studies discussed above, can be based on
misunderstanding.Moreover,ananti-atheroscleroticdrug
Allicor, a derivative of garlic, was developed on the basis
of the cell culture experiments. Anti-atherosclerotic effi-
cacy of Allicor was confirmed by clinical trials [24], [25].
Discussing the mode of action of the Allicor, both articles
refer to the cell culture study [8]. In fact, the results of
the trials [24], [25] are at variance with those of the cell
culture experiments: if garlic indeed lowers the intake of
Chbytheculturedsmoothmusclecells[9],itmightcause
elevation of serum Ch in vivo. It is written in [25] with
reference to a review [26], obviously implying effective-
ness of garlic: “Lipid-lowering properties of garlic-based
drugs and preparations are studied rather well” [25].
However, it is stated in [26] that there is increasingly less
evidence for lipid lowering properties of garlic prepara-
tions.Alaterreviewonthistopicconcludedthatevidence,
basedonrigorousclinicaltrialsofgarlic,isnotconvincing
[27]. For hypercholesterolemia, the reported effects of
garlic are small and may be of no clinical relevance [27].
Previously we discussed other trials on hypercholester-
olemia, results of which have not been convincingly con-
firmed by other researchers [28]. The matter could be
clarifiedbymeansofalarge-scaleindependenttrial.Note
that Allicor is produced by INAT Farma fused with the In-
stitute of Aterosclerosis Research (http://inat.ru), where
theabove-mentionedcellcultureexperimentshavebeen
performed. With pharmaceutical costs increasing faster
thanmostotherhealthcareexpenditures,studiesshould
meet the needs of evidence-based treatments and not
just the needs of the manufacturers [1].
The material from this paper was presented at several
conferences (e.g., [29]); and the author was asked, why
itisfocusedonreportsofmostlyoneresearchgroupand
the topic is not discussed in a broader perspective. In
fact, there have been no other studies, where serum
atherogenicityandatherogenic/antiatherogenicpotencies
of drugs were evaluated directly on cell cultures and
practical recommendations given on the basis of such
evaluations.Earlierexperimentswithculturingofsmooth
muscle cells from atherosclerotic plaques [30], culturing
or incubation of different cells in lipoprotein-containing
media (e.g., [31], [32]) included neither measurement of
serumatherogenicitynordrugevaluations.Inconclusion,
a reason for submitting this paper to an open access
journalistodrawtheattentionofthescientificcommunity
to the fact that doubtful information was published in
numerous pharmacological, clinical and other editions
(e.g. [7], [10], [12], [33], [34], [35]) including a recently
published Russian-language handbook, and is still being
referred to in more recent studies (e.g. [36], [37], [38]).
However, the study [38] disagreed with the results of
someexperimentsbytheresearchgroupunderdiscussion
in this paper; and an artifact in these experiments was
proposed as an explanation for the disagreement.
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